

# **Data Sheet**

Research Use Only

# Compound Name

### **Alternative Names**

SB431542

4-[4-(1,3-Benzodioxol-5-yl)-5-(pyridin-2-yl)-1Himidazol-2-yl]benzamide

Catalog Number

**SM33** 

# **Activity**

# **Effect**

SB431542 is a potent and selective inhibitor of the transforming growth factor-\( \beta \) superfamily type 1 (TGF-β1) activin receptor-like kinase (ALK5) receptors, and its relatives ALK4 and ALK7. It does not affect the BMP receptors ALK2, ALK3, ALK6. SB431542 inhibits the TGF-\u03b3-mediated activation of SMAD proteins, expression of collagen and fibronectin, cell proliferation and cell motility. It does not inhibit kinases that are activated in response to serum or stress such as ERK, p38 or JNK.

SB431542 suppresses TGF-β-induced proliferation of human osteosarcoma cells. SB431542 treatment of glioma cultures inhibited proliferation, TGF-betamediated morphologic changes, and cellular motility. Small molecule inhibitors of TGF-beta receptors may offer a novel therapy for malignant gliomas by reducing cell proliferation, angiogenesis, and motility

#### **Purity**

>99%

**CAS** 

Formula

Molecular Weight

301836-41-9

 $C_{22}H_{16}N_4O_3$ 

384.39

Solubility

**Stability** 

**DMSO** 

Stable at -20°C. Keep away from direct sunlight.

#### References

- 1. Laping, NJ., et al. 2002. Mol Pharmacol. 62(1): 58-64. PMID: 12065755
- 2. Hjelmeland, MD., et al. 2004. Mol Cancer Ther. 3(6): 737-745. PMID: 15210860
- 3. Lei, Y. and Schaffer, DV. 2013. Proc Natl Acad Sci U S A. 110(52): E5039-5048. PMID: 24248365